Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Apellis Pharmaceuticals, Inc. - Common Stock
(NQ:
APLS
)
17.64
-0.62 (-3.40%)
Streaming Delayed Price
Updated: 2:53 PM EDT, Jul 7, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Apellis Pharmaceuticals, Inc. - Common Stock
< Previous
1
2
...
12
13
14
15
16
17
18
19
Next >
Apellis Pharmaceuticals to Host Conference Call on Nov 7, 2022 to Discuss Third Quarter 2022 Financial Results
October 31, 2022
From
Apellis Pharmaceuticals, Inc.
Via
GlobeNewswire
7 Analysts Have This to Say About Apellis Pharmaceuticals
October 18, 2022
Over the past 3 months, 7 analysts have published their opinion on Apellis Pharmaceuticals (NASDAQ:APLS) stock. These analysts are typically employed by large Wall Street banks and tasked with...
Via
Benzinga
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 07, 2022
From
Apellis Pharmaceuticals, Inc.
Via
GlobeNewswire
Where Apellis Pharmaceuticals Stands With Analysts
September 08, 2022
Within the last quarter, Apellis Pharmaceuticals (NASDAQ:APLS) has observed the following analyst ratings:
Via
Benzinga
Apellis's Pegcetacoplan Shows Increased Effects In Geographic Atrophy At Two Years
August 24, 2022
Via
Benzinga
Where Apellis Pharmaceuticals Stands With Analysts
August 09, 2022
Within the last quarter, Apellis Pharmaceuticals (NASDAQ:APLS) has observed the following analyst ratings:
Via
Benzinga
Why Oil-Related Stocks Traded Higher; Here Are 74 Biggest Movers From Yesterday
October 04, 2022
Gainers LogicBio Therapeutics, Inc. (NASDAQ: LOGC) shares surged 637.6% to close at $2.01 on Monday after the company announced it will be acquired by AstraZeneca's subsidiary, Alexion, for $2.07 per...
Via
Benzinga
HC Wainwright Initiates Coverage On Upcoming Complement Franchise Company Apellis Pharmaceuticals
July 19, 2022
Via
Benzinga
Small-Cap Catalyst Pharma Is Among Market's Best Price Performers
October 04, 2022
Small-cap biotech Catalyst Pharmaceuticals has been outperforming the broader market amid earnings and revenue acceleration. It joined the S&P 600 last month.
Via
MarketBeat
Topics
Stocks
Why Tesla Shares Are Trading Lower By Over 7%, Here Are 52 Stocks Moving In Monday's Mid-Day Session
October 03, 2022
Gainers LogicBio Therapeutics, Inc. (NASDAQ: LOGC) gained 641% to $2.0207 after the company announced it will be acquired by AstraZeneca's subsidiary, Alexion, for $2.07 per share.
Via
Benzinga
Why Top-Rated Biotechs Apellis, Belite Are Among The Worst Performers Today
October 03, 2022
Both companies presented data at the American Academy of Ophthalmology meeting.
Via
Investor's Business Daily
Investigator Says Apellis' Lead Product Shows 'First Direct Evidence Of Slowing Geographic Atrophy Lesion Growth'
October 03, 2022
Via
Benzinga
Apellis Announces 24-Month Phase 3 Post Hoc Results Showing Treatment with Pegcetacoplan Led to Preservation of Function in High-Risk Areas of the Retina in Patients with Geographic Atrophy (GA) at AAO Annual Meeting
September 30, 2022
From
Apellis Pharmaceuticals, Inc.
Via
GlobeNewswire
Apellis Announces Four Oral Presentations of Data from the Phase 3 DERBY and OAKS Studies of Pegcetacoplan in Geographic Atrophy (GA) to be Presented at the American Academy of Ophthalmology Annual Meeting
September 30, 2022
From
Apellis Pharmaceuticals, Inc.
Via
GlobeNewswire
10 Health Care Stocks Whale Activity In Today's Session
September 29, 2022
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity...
Via
Benzinga
Stifel Maintains Buy Rating for Apellis Pharmaceuticals: Here's What You Need To Know
September 08, 2022
Stifel has decided to maintain its Buy rating of Apellis Pharmaceuticals (NASDAQ:APLS) and raise its price target from $60.00 to $65.00. Shares of Apellis Pharmaceuticals are trading up 2.69% over the...
Via
Benzinga
Moderna To $165? Plus This Analyst Cuts PT On FedEx
September 08, 2022
Deutsche Bank raised the price target on Moderna, Inc. (NASDAQ: MRNA) from $155 to $165. Deutsche Bank analyst Emmanuel Papadakis also upgraded the stock from Hold to Buy. Moderna shares rose 2.8% to...
Via
Benzinga
Advance Auto Parts, Nordstrom And Other Big Stocks Recording Losses On Wednesday
August 25, 2022
U.S. stocks closed higher with the Nasdaq Composite gaining 50 points on Wednesday. Here is the list of some big stocks moving lower in the previous session.
Via
Benzinga
Why Minerva Neurosciences Shares Traded Higher By Over 66%; Here Are 78 Biggest Movers From Yesterday
August 25, 2022
Gainers Minerva Neurosciences, Inc. (NASDAQ: NERV) shares gained 66.5% to close at $7.51 after Point72 Asset Management reported an 8.8% passive stake in the company.
Via
Benzinga
Recap Of Wednesday's Biotech Catalysts - End Of the Day Summary
August 24, 2022
Via
Benzinga
Apellis Shares Show Mixed Reaction After Positive 2 Years Data From Late-Stage Retinal Disorder Study
August 24, 2022
Apellis Pharmaceuticals (NASDAQ: APLS) revealed top-line data readout at 24 months showing increased effects over time with intravitreal pegcetacoplan in the Phase 3 DERBY and OAKS studies in...
Via
Benzinga
7 Cheap Biotech Stocks to Buy Now
August 03, 2022
These cheap biotech stocks to buy offer investors a way to get ready for the inevitable comeback in the biopharmaceutical sector.
Via
InvestorPlace
Apellis Announces Agreements to Exchange Approximately $75.6 Million in Principal Amount of Its 3.500% Convertible Senior Notes Due 2026 for Common Stock
July 27, 2022
From
Apellis Pharmaceuticals, Inc.
Via
GlobeNewswire
Why Crypto-Related Companies Traded Higher; Here Are 72 Biggest Movers From Yesterday
July 20, 2022
Gainers Applied Blockchain, Inc. (NASDAQ: APLD) shares climbed 100% to close at $2.12 on Tuesday after the company reported a 200-megawatt five-year hosting contract with Marathon Digital Holdings and...
Via
Benzinga
Recap of Tuesday's Biotech Catalysts - End Of The Day Summary
July 19, 2022
The U.S. Food and Drug Administration (FDA) has granted tentative approval to Avadel Pharmaceuticals’ (NASDAQ: AVDL) lead candidate LUMRYZ (FT218) for the treatment of excessive daytime sleepiness...
Via
Benzinga
Nasdaq Rises More Than 300 Points; Crude Oil Moves Higher
July 19, 2022
U.S. stocks extended gains toward the end of trading, with the Nasdaq Composite gaining around 3% on Tuesday.
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
July 19, 2022
Via
Benzinga
Dow Climbs Over 500 Points as Upbeat Earnings Roll In
July 19, 2022
The Dow Jones Industrial Average is up 510 points midday, as the newest string of earnings reports shows companies working through the current economic pressures.
Via
Talk Markets
Dow Surges 500 Points; Johnson & Johnson Lowers Guidance
July 19, 2022
U.S. stocks traded higher midway through trading, with the Dow Jones gaining around 500 points on Tuesday.
Via
Benzinga
This Financial Services Stock Is Trading Higher By 50%, Here Are 40 Stocks Moving In Tuesday's Mid-Day Session
July 19, 2022
Gainers Applied Blockchain, Inc. (NASDAQ: APLD) jumped 50.1% to $1.5907 after the company reported a 200-megawatt five-year hosting contract with Marathon Digital Holdings and raised its Q4 revenue...
Via
Benzinga
< Previous
1
2
...
12
13
14
15
16
17
18
19
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms Of Service
.